Dorzolamide-d5 (hydrochloride) (Synonyms: L-671,152-d5, MK-507-d5) |
| Catalog No.GC47267 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2749856-75-3
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Dorzolamide-d5 is intended for use as an internal standard for the quantification of dorzolamide by GC- or LC-MS. Dorzolamide is an inhibitor of carbonic anhydrase (CA), inhibiting CAII, CAV, CAVI, CAIX, CAXII, CAXIII, and CAXIV with Ki values ranging from 3.5 to 52 nM.1,2,3 It is selective for these isoforms over CAI, CAIII, and CAIV (Kis = 50, 8, and 8.5 μM, respectively).1 Dorzolamide inhibits carbonic anhydrase in isolated rabbit iris-ciliary body by 87% when used at a concentration of 0.02%.3 It also reduces intraocular pressure in an α-chymotrypsin-treated rabbit model of ocular hypertension and in normotensive rabbits when applied topically at a concentration of 0.5%.3 Formulations containing dorzolamide have been used in the treatment of glaucoma.4,5
1.Supuran, C.T., and Scozzafava, A.Carbonic anhydrases as targets for medicinal chemistryBioorganic & Medicinal Chemistry15(13)4336-4350(2007) 2.Greer, J., Erickson, J.W., Baldwin, J.J., et al.Application of the three-dimensional structures of protein target molecules in structure-based drug designJournal of Medicinal Chemistry37(8)1035-1054(1994) 3.Hunt, C.A., Mallorga, P.J., Michelson, S.R., et al.3-Substituted thieno[2,3-b][1,4]thiazine-6-sulfonamides. A novel class of topically active carbonic anhydrase inhibitorsJournal of Medicinal Chemistry37(2)240-247(1994) 4.Loftsson, T., Jansook, P., and StefÁnsson, E.Topical drug delivery to the eye: DorzolamideActa. Ophthalmol.90(7)603-608(2012) 5.Cheng, J.W., Cheng, S.W., Gao, L.D., et al.Intraocular pressure-lowering effects of commonly used fixed-combination drugs with Timolol: A systematic review and meta-analysisPLoS One7(9)45079(2012)
| Cas No. | 2749856-75-3 | SDF | |
| Synonyms | L-671,152-d5, MK-507-d5 | ||
| Canonical SMILES | O=S1([C@@H](C)C[C@H](NC([2H])([2H])C([2H])([2H])[2H])C2=C1SC(S(N)(=O)=O)=C2)=O.Cl | ||
| Formula | C10H11D5N2O4S3.HCl | M.Wt | 365.9 |
| Solubility | DMSO: soluble,Methanol: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.733 mL | 13.6649 mL | 27.3299 mL |
| 5 mM | 0.5466 mL | 2.733 mL | 5.466 mL |
| 10 mM | 0.2733 mL | 1.3665 mL | 2.733 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *